212 related articles for article (PubMed ID: 527342)
1. Intravaginal contraception with the synthetic progestin, R2010.
Toivonen J
Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
4. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
6. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of LH release with synthetic LH-RH (author's transl)].
Koyama T
Nihon Naibunpi Gakkai Zasshi; 1976 Sep; 52(9):881-97. PubMed ID: 828583
[TBL] [Abstract][Full Text] [Related]
8. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
9. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
[TBL] [Abstract][Full Text] [Related]
10. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
11. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
12. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
13. The use of a contraceptive vaginal ring governed by the pattern of individual uterine bleeding.
Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1979 Apr; 19(4):401-9. PubMed ID: 455988
[TBL] [Abstract][Full Text] [Related]
14. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
15. Pituitary and gonadal function during the use of progesterone- or progesterone-estradiol-releasing vaginal rings.
Toivonen J
Int J Fertil; 1980; 25(2):106-11. PubMed ID: 6117523
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
18. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]